NEXI-002

N/A

Report date: 2022/12/15 20:00:39

Base Information

Drug NameNEXI-002

Drug Alias NameNEXI-002

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityWilms' Tumour 1 modulators +[6]

TargetsSLAM family member 7Wilms' Tumour 1Syndecan-1 +[4]

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesNeximmune Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNeximmune Inc

Active IndicationsN/A

Inactive IndicationsMultiple Myeloma

Other Information

ATC CodeN/A